
|Videos|June 30, 2022
What the impact of 44-week aflibercept data may mean in a real-world setting
Author(s)Sheryl Stevenson, Emily Kaiser Maharjan
David Brown, MD, highlights his ASRS poster that includes 44-week data for a four-times-higher dose of aflibercept in a real-world setting.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Port Delivery System Therapies in Retinal Vascular Diseases
2
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
3
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
4
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
5






















